CompanyGraph
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
T14 · China
Price data from its 2TZ listing on XSTU, quoted in EUR
jydrt.com.cnFinancials as of FY2025
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $4.03B, above the global median of $1.15B
- FinancialsAltman Z-Score 5.52: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
12.39%Above 5Y avg (7.76%)
Annual Rate
USD 0.34Paid annual
Payout Ratio
131.7%High
Payback Period
6.3 yr
Last Ex-Dividend
Jun 29, 2026
The reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
4.03BUSDvs all stocks (USD)
Trailing P/E
6.64xRevenue (TTM)
734.94MUSDvs all stocks (USD)
Profit Margin
43.81%Beta
0.5920xvs all stocks
52-Week Change
11.60%vs all stocks
Market Capitalization
4.03BUSDvs all stocks (USD)
Enterprise Value
64.72MUSDvs all stocks (USD)
Trailing P/E
6.64xForward P/E
10.73xPrice to Sales (TTM)
0.7232xPrice to Book (MRQ)
1.93xEnterprise to Revenue
0.0880xEnterprise to EBITDA
0.3880xGross Margin
77.71%Profit Margin
43.81%Operating Margin
32.97%Return on Assets (TTM)
5.92%Return on Equity (TTM)
27.46%Revenue (TTM)
734.94MUSDvs all stocks (USD)
Revenue per Share (TTM)
6.46USDUpdated Jul 19, 2026Quarterly Revenue Growth
4.10%Gross Profit (TTM)
547.45MUSDvs all stocks (USD)
Net Income (TTM)
321.98MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
13.20%Operating Cash Flow (TTM)
77.92MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
77.39MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.3445USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
12.39%vs all stocks
5-Year Average Dividend Yield
7.76%vs all stocks
Payout Ratio
131.70%Minority Interest (Equity)
445.69KCNYFY2025 · Dec 31, 2025Revenue
4.92BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.28BCNYFY2025 · Dec 31, 2025Gross Profit
3.64BCNYFY2025 · Dec 31, 2025Operating Income
971.15MCNY143.95M · vs all stocks (USD)
Pre-tax Income
2.49BCNYFY2025 · Dec 31, 2025Income Tax Expense
376.70MCNYFY2025 · Dec 31, 2025Net Income
2.11BCNYFY2025 · Dec 31, 2025EBIT
2.50BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
2.77BCNYFY2025 · Dec 31, 2025Research & Development
189.81MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
1.79BCNYFY2025 · Dec 31, 2025Other Operating Expenses
80.21MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
41.84MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
9.16MCNYFY2025 · Dec 31, 2025EPS (Basic)
2.77CNYFY2025 · Dec 31, 2025EPS (Diluted)
2.77CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
769.32MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
769.32MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
2.11BCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
20.27MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
1.95BCNYFY2025 · Dec 31, 2025Free Cash Flow
1.83BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.02BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
2.11BCNYFY2025 · Dec 31, 2025Other Non-cash Items
10.35MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-260.42MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
85.38MCNYFY2025 · Dec 31, 2025Capital Expenditures
-118.22MCNYFY2025 · Dec 31, 2025Net Acquisitions
0.00CNYFY2025 · Dec 31, 2025Purchase of Investments
-5.98BCNYFY2025 · Dec 31, 2025Sale of Investments
4.69BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.41BCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
5.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-2.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-981.29MCNYFY2025 · Dec 31, 2025Other Financing Charges
-2.60MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-980.88MCNYFY2025 · Dec 31, 2025Shares Outstanding
770.09MSharesUpdated Jul 19, 2026Float Shares
426.53MSharesUpdated Jul 19, 2026% Held by Insiders
8.80%vs all stocks
% Held by Institutions
0.14%vs all stocks
Total Cash (MRQ)
261.03MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.30USDUpdated Jul 19, 2026Total Debt (MRQ)
8.54MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0077xCurrent Ratio (MRQ)
2.16xBook Value per Share (MRQ)
1.44USDUpdated Jul 19, 2026Total Assets
11.69BCNY1.73B · vs all stocks (USD)
Total Current Assets
7.15BCNYFY2025 · Dec 31, 2025Total Liabilities
4.59BCNYFY2025 · Dec 31, 2025Total Non-current Assets
4.54BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
83.35MCNYFY2025 · Dec 31, 2025Total Current Liabilities
4.51BCNYFY2025 · Dec 31, 2025Cash
274.40MCNYFY2025 · Dec 31, 2025Cash Equivalents
742.02MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.02BCNYFY2025 · Dec 31, 2025Accounts Receivable
973.20MCNYFY2025 · Dec 31, 2025Inventory
1.13BCNYFY2025 · Dec 31, 2025Short-term Debt
61.03MCNYFY2025 · Dec 31, 2025Other Current Liabilities
54.94MCNYFY2025 · Dec 31, 2025Long-term Debt
4.66MCNYFY2025 · Dec 31, 2025Common Stock (Book)
770.09MCNYFY2025 · Dec 31, 2025Retained Earnings
4.89BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
7.10BCNY1.05B · vs all stocks (USD)
52-Week Low
2.48USDUpdated Jul 19, 202652-Week High
3.75USDUpdated Jul 19, 202652-Week Change
11.60%vs all stocks
Beta
0.5920xvs all stocks
50-Day MA
3.04USDUpdated Jul 19, 2026200-Day MA
3.15USDUpdated Jul 19, 2026Avg 10-Day Volume
203.44KSharesUpdated Jul 19, 2026Avg 30-Day Volume
221.45KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
0.4200USDUpdated Jul 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 321,983,965Operating Cash Flow (USD, TTM): 77,921,590
Financial Health
Altman Z-Score 5.52: safe zoneNotable
Altman Z-Score: 5.52
High structural barrier to entryNotable
Barrier to Entry: 0.56
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $4.03B, above the global median of $1.15BNotable
Market cap (USD): 4,025,106,899Global Median: 1,146,734,693.424
Revenue is $734.94M, above the global median of $520.53MNotable
Revenue (USD): 734,939,267Global Median: 520,528,949.311
Levered free cash flow is $77.39M, above the global median of $16.24MNotable
Levered free cash flow (USD): 77,394,384Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
J.B. Chemicals & Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
HLB Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Dyne Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
China Medical System Holdings Limited
Tier 1ProductionApproval-Gated PipelineRule
Livzon Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Pharmaceutical Da Ren Tang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Xiamen Amoytop Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xuanzhu Biopharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Sundaram Finance Holdings Limited
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Thyrocare Technologies Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Mphasis Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities